HALOZYME THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Halozyme Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Halozyme Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $137M, a 67.4% increase year-over-year.
  • Halozyme Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $392M, a 54.6% increase year-over-year.
  • Halozyme Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $282M, a 39.3% increase from 2022.
  • Halozyme Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $202M, a 49.8% decline from 2021.
  • Halozyme Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $403M, a 212% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $392M $137M +$55.2M +67.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $337M $93.2M +$18.5M +24.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $319M $76.8M +$37.2M +93.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $282M $85.4M +$27.7M +48% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $254M $81.8M +$20.2M +32.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $234M $74.8M +$52.1M +230% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $182M $39.6M -$20.5M -34.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $202M $57.7M -$9.07M -13.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $211M $61.6M -$155M -71.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $366M $22.7M -$68.8M -75.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $435M $60.1M +$32.2M +115% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $403M $66.8M -$6.39M -8.74% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $409M $217M +$180M +498% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $229M $91.5M +$65.6M +254% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $163M $27.9M +$34M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $129M $73.2M +$108M Oct 1, 2020 Dec 31, 2020 10-K 2021-02-23
Q3 2020 $21.5M $36.2M +$61.2M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$39.7M $25.8M +$40.4M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$80.1M -$6.1M -$7.9M -440% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$72.2M -$34.4M -$32.3M -1518% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-23
Q3 2019 -$40M -$25M +$2.84M +10.2% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-23
Q2 2019 -$42.8M -$14.6M +$8.27M +36.1% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-23
Q1 2019 -$51.1M $1.8M +$29.3M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-23
Q4 2018 -$80.3M -$2.13M -$126M -102% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-24
Q3 2018 $45.7M -$27.9M -$30.6M -1113% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-24
Q2 2018 $76.3M -$22.9M +$7.87M +25.6% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-24
Q1 2018 $68.4M -$27.5M +$5.44M +16.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-24
Q4 2017 $63M $124M +$151M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-21
Q3 2017 -$88.3M $2.75M +$31.7M Jul 1, 2017 Sep 30, 2017 10-K 2019-02-21
Q2 2017 -$120M -$30.8M -$3.89M -14.5% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-21
Q1 2017 -$116M -$32.9M -$13.1M -66% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-21
Q4 2016 -$103M -$27.4M $0 0% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-20
Q3 2016 -$103M -$28.9M $0 0% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-20
Q2 2016 -$103M -$26.9M $0 0% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-20
Q1 2016 -$103M -$19.8M $0 0% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-20
Q4 2015 -$103M -$27.4M -$22.1M -419% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-28
Q3 2015 -$80.9M -$28.9M -$8.67M -42.7% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-28
Q2 2015 -$72.2M -$26.9M -$10.6M -65.2% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-28
Q1 2015 -$61.6M -$19.8M +$6.73M +25.4% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-28
Q4 2014 -$68.4M -$5.27M +$16.7M +76% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-29
Q3 2014 -$85.1M -$20.3M -$988K -5.12% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-29
Q2 2014 -$84.1M -$16.3M +$6.64M +29% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-29
Q1 2014 -$90.7M -$26.5M -$7.26M -37.6% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-29
Q4 2013 -$83.5M -$22M -$17.6M -399% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-02
Q3 2013 -$65.9M -$19.3M +$714K +3.57% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-02
Q2 2013 -$66.6M -$22.9M -$8.89M -63.4% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-02
Q1 2013 -$57.7M -$19.3M -$4.17M -27.6% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-02
Q4 2012 -$53.6M -$4.41M +$14M +76.1% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-28
Q3 2012 -$67.6M -$20M -$25.2M -487% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-28
Q2 2012 -$42.4M -$14M -$17.1M -550% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-28
Q1 2012 -$25.3M -$15.1M -$5.48M -56.9% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-28
Q4 2011 -$19.8M -$18.4M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-01
Q3 2011 $5.17M +$17.6M Jul 1, 2011 Sep 30, 2011 10-K 2013-03-01
Q2 2011 $3.12M +$15.3M Apr 1, 2011 Jun 30, 2011 10-K 2013-03-01
Q1 2011 -$9.64M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-01
Q3 2010 -$12.4M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$12.2M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.